News

Chr. Hansen recognised for probiotic microbe screening

A panel of leading industry experts has selected Chr. Hansen as one of three emerging science winners, for the company’s in vitro microbe screening platform. The platform enables identification of microbes capable of modifying the function of human immune cells. These capabilities are expected to exert a health benefit in conditions of excessive inflammation and […]

A panel of leading industry experts has selected Chr. Hansen as one of three emerging science winners, for the company’s in vitro microbe screening platform. The platform enables identification of microbes capable of modifying the function of human immune cells.

These capabilities are expected to exert a health benefit in conditions of excessive inflammation and the platform is currently being expanded to be used in Chr. Hansen’s large bacteria screening programs.

“In the support of our current probiotic products, and in the development of the next generation products, generating high quality scientific data and maintaining the best possible scientific documentation is key,” said Benedicte Flambard, Vice President, Chr. Hansen Health & Nutrition Innovation. “We build our understanding of all our microbes using multiple in vitro and ex vivo platforms along with manufacturing characteristics and this award demonstrates the importance of such insight.”